Director-General of Africa Centers for Disease Control and Prevention visits SK bioscience to discuss localization of vaccines in Africa

• Dr. Ho Jean CassiaGeneral manager Africa Centers for Disease Control and Prevention (Africa CDC), visited SK Bioscience to discuss the localization plan for vaccines on the African continent.
• SK bioscience has launched a “glocalization project” that aims to transplant R&D and manufacturing capabilities to countries that lack adequate vaccine infrastructure.

Seongnam City, South Korea, November 5, 2023 /PRNewswire/ — SK bioscience, an innovative vaccine and biotechnology company committed to promoting human health from prevention to treatment, announced, Jean Cassiadirector general for africa CDC Visit SK Biotechnology Headquarters November 3

Discuss collaboration with the Partnership for African Vaccine Manufacturing (PAVM).

Dr. Kaseya Appointed Director General for Africa CDC exist February 2023. He is currently visiting partners to strengthen partnerships and closer collaboration on public health matters in Africa, with a particular focus on local manufacturing.

PAVM, by african union (AU) 2021, aiming to achieve an ambitious goal. The goal is that by 2040, African vaccine manufacturing will be able to produce and supply more than 60% of the total vaccine doses required by the continent. This is a significant increase from the current level of less than 1%. The medium-term goal is to reach 10% by 2025 and 30% by 2030.

Africa CDC Plans secure a portfolio of vaccines to address various diseases, including tuberculosis, hepatitis B, HIV, malaria, Ebola and an unknown infectious disease (Disease X). This will be achieved through strategic partnerships with global companies and the establishment of vaccine research and development (R&D) and manufacturing infrastructure, including local factories and cold chain logistics.

SK bioscience launched the “Glocalization Project,” a mid- to long-term core strategy involving the transfer of R&D and manufacturing capabilities to countries with insufficient vaccine infrastructure to support PAVM.

In July, SK Bioscience signed an agreement with South Korea government pharmaceutical organization (GPO), a state-owned pharmaceutical company Thailand3. Strengthen vaccine infrastructure construction. In September, the two parties signed a memorandum of understanding (MOU) republic of serbia The two parties have established a strategic partnership in the field of vaccine research and development and production.

After the discussion, Dr. Kaseya The visiting committee members visited the R&D center of SK bioscience and observed the technical know-how of vaccine development.

Dr. Ho Jean Cassiadirector general for africa CDC Said: “I had the opportunity to learn about SK bioscience Glocalization project Regional Vaccine Manufacturing Cooperation Organization, hosted by Geneva Last May.Today’s visit is of great significance and allows us to gain a deeper understanding of Glocalization project and tours of research and development facilities. African The new public health order calls for scaling up production of vaccines, diagnostics and therapeutics. We are actively seeking partnerships, particularly in the area of ​​research and development, to help us achieve PAVM’s ambitious goals. “

An ZaiyongCEO of SK Bioscience stated: “Glocalization project is an innovative business model that goes beyond just setting up local factories. It addresses inequalities in vaccine supply and enables rapid response to new epidemics. By working with governments, institutions and companies, we aim to lead efforts to prevent future pandemics. “

About SK Bioscience
SK bioscience is an innovative vaccine and biotechnology company dedicated to vaccine development and manufacturing to achieve more equitable access to vaccines around the world. SK bioscience utilizes its cutting-edge technological advantages to promote global human health from prevention to treatment. In collaboration with domestic and foreign governments, regulatory agencies, healthcare providers, doctors and medical experts, all colleagues at SK are passionately committed to providing high-quality vaccines and better public healthcare solutions to those in need .

– SK bioscience website
– SK Bioscience LinkedIn

related Africa Centers for Disease Control and Prevention (Africa CDC)
Africa Centers for Disease Control and Prevention (Africa CDC) is an autonomous public health agency in mainland China african union It supports Member States’ efforts to strengthen health systems and improve disease surveillance, emergency response, prevention and control.

For more information, visit https://africacdc.org/

touch
SK bioscience communications team
Kim Chang-hyun((email protected))Jenny S. Parker((email protected))Kim Tae Kyun((email protected))

View original content to download multimedia: https://www.prnewswire.com/news-releases/africa-cdc-director-general-visits-sk-bioscience-to-discuss-vaccine-localization-in-africa-301977821.html

SOURCE SK Bioscience